Shuk-Mei Ho
Concepts (588)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phenols | 30 | 2025 | 94 | 7.170 |
Why?
| | Benzhydryl Compounds | 28 | 2021 | 70 | 6.160 |
Why?
| | Prostatic Neoplasms | 36 | 2022 | 401 | 5.300 |
Why?
| | Epigenesis, Genetic | 22 | 2025 | 412 | 4.220 |
Why?
| | DNA Methylation | 28 | 2025 | 592 | 4.210 |
Why?
| | Prostate | 24 | 2020 | 118 | 3.970 |
Why?
| | Estradiol | 21 | 2021 | 215 | 3.590 |
Why?
| | Endocrine Disruptors | 17 | 2025 | 34 | 3.280 |
Why?
| | Estrogen Receptor beta | 17 | 2019 | 54 | 2.830 |
Why?
| | Prenatal Exposure Delayed Effects | 11 | 2021 | 214 | 2.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 20 | 2024 | 868 | 2.250 |
Why?
| | Environmental Exposure | 12 | 2024 | 222 | 2.190 |
Why?
| | Maternal Exposure | 6 | 2025 | 103 | 1.850 |
Why?
| | Asthma | 6 | 2018 | 319 | 1.630 |
Why?
| | CpG Islands | 10 | 2025 | 114 | 1.620 |
Why?
| | Estrogens | 13 | 2020 | 224 | 1.610 |
Why?
| | Environmental Pollutants | 7 | 2024 | 110 | 1.550 |
Why?
| | Testosterone | 8 | 2016 | 142 | 1.510 |
Why?
| | Air Pollutants | 6 | 2018 | 75 | 1.450 |
Why?
| | Air Pollutants, Occupational | 4 | 2020 | 14 | 1.420 |
Why?
| | Occupational Exposure | 4 | 2021 | 106 | 1.370 |
Why?
| | Pregnancy | 25 | 2025 | 2610 | 1.200 |
Why?
| | Animals | 57 | 2024 | 13528 | 1.180 |
Why?
| | Spermatogenesis | 2 | 2021 | 16 | 1.180 |
Why?
| | Promoter Regions, Genetic | 12 | 2019 | 465 | 1.160 |
Why?
| | Male | 73 | 2022 | 27444 | 1.150 |
Why?
| | Rats | 25 | 2021 | 3164 | 1.120 |
Why?
| | Benzo(a)pyrene | 4 | 2018 | 13 | 1.110 |
Why?
| | Diet, High-Fat | 4 | 2021 | 243 | 1.060 |
Why?
| | Humans | 93 | 2025 | 53246 | 1.030 |
Why?
| | Breast Neoplasms | 10 | 2016 | 1223 | 1.020 |
Why?
| | Cell Line, Tumor | 25 | 2024 | 1470 | 0.980 |
Why?
| | Gene Expression Profiling | 11 | 2015 | 1112 | 0.960 |
Why?
| | Receptors, Estrogen | 6 | 2019 | 134 | 0.930 |
Why?
| | Female | 56 | 2025 | 28792 | 0.920 |
Why?
| | Centrosome | 2 | 2016 | 11 | 0.910 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2017 | 122 | 0.910 |
Why?
| | Racemases and Epimerases | 3 | 2011 | 18 | 0.910 |
Why?
| | Fetal Blood | 6 | 2025 | 79 | 0.900 |
Why?
| | Diet | 4 | 2019 | 611 | 0.900 |
Why?
| | Veterans | 2 | 2021 | 580 | 0.860 |
Why?
| | Disease Susceptibility | 5 | 2012 | 96 | 0.840 |
Why?
| | Adenocarcinoma | 5 | 2015 | 405 | 0.830 |
Why?
| | Butter | 2 | 2021 | 4 | 0.830 |
Why?
| | Sex Characteristics | 4 | 2018 | 204 | 0.810 |
Why?
| | Rats, Sprague-Dawley | 15 | 2021 | 1544 | 0.790 |
Why?
| | Metallothionein | 2 | 2015 | 9 | 0.770 |
Why?
| | Cell Movement | 4 | 2014 | 279 | 0.750 |
Why?
| | Genetic Predisposition to Disease | 5 | 2015 | 533 | 0.730 |
Why?
| | Response Elements | 2 | 2013 | 29 | 0.730 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2024 | 89 | 0.720 |
Why?
| | Interferon-gamma | 2 | 2013 | 174 | 0.700 |
Why?
| | Infertility, Male | 1 | 2021 | 12 | 0.700 |
Why?
| | Estrogens, Non-Steroidal | 8 | 2015 | 15 | 0.700 |
Why?
| | Cell Proliferation | 10 | 2017 | 1031 | 0.680 |
Why?
| | Signal Transduction | 14 | 2020 | 1748 | 0.680 |
Why?
| | Dietary Fats | 1 | 2021 | 133 | 0.660 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 10 | 2016 | 579 | 0.640 |
Why?
| | Toxicity Tests | 1 | 2020 | 57 | 0.640 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2020 | 42 | 0.630 |
Why?
| | MicroRNAs | 5 | 2016 | 397 | 0.630 |
Why?
| | Sexual Maturation | 2 | 2018 | 19 | 0.610 |
Why?
| | Electronic Waste | 3 | 2018 | 3 | 0.610 |
Why?
| | Aging | 4 | 2017 | 715 | 0.590 |
Why?
| | Gene Regulatory Networks | 3 | 2017 | 112 | 0.580 |
Why?
| | Transcription, Genetic | 6 | 2013 | 374 | 0.580 |
Why?
| | Prostatic Intraepithelial Neoplasia | 4 | 2015 | 8 | 0.570 |
Why?
| | Military Personnel | 1 | 2020 | 173 | 0.560 |
Why?
| | Epigenomics | 2 | 2016 | 76 | 0.550 |
Why?
| | Stress, Psychological | 1 | 2020 | 283 | 0.550 |
Why?
| | Chromosomes, Human, X | 1 | 2018 | 18 | 0.550 |
Why?
| | Depressive Disorder | 1 | 2020 | 336 | 0.540 |
Why?
| | Reproduction | 2 | 2016 | 64 | 0.540 |
Why?
| | Anxiety | 1 | 2020 | 321 | 0.530 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2016 | 58 | 0.530 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.520 |
Why?
| | Embryonic Development | 2 | 2015 | 18 | 0.520 |
Why?
| | Microtubules | 2 | 2016 | 35 | 0.520 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.510 |
Why?
| | Transcriptome | 2 | 2021 | 368 | 0.510 |
Why?
| | Cell Transformation, Neoplastic | 5 | 2017 | 187 | 0.510 |
Why?
| | Gene-Environment Interaction | 2 | 2019 | 41 | 0.500 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2020 | 1367 | 0.500 |
Why?
| | Research Design | 2 | 2019 | 373 | 0.500 |
Why?
| | Rats, Inbred Strains | 6 | 2015 | 174 | 0.500 |
Why?
| | Gene Expression Regulation | 7 | 2018 | 1003 | 0.490 |
Why?
| | Vehicle Emissions | 3 | 2017 | 10 | 0.490 |
Why?
| | Epithelial Cells | 4 | 2015 | 218 | 0.480 |
Why?
| | DNA | 3 | 2016 | 535 | 0.480 |
Why?
| | Environmental Health | 1 | 2016 | 14 | 0.470 |
Why?
| | Halogenated Diphenyl Ethers | 2 | 2013 | 4 | 0.470 |
Why?
| | Prostatic Hyperplasia | 3 | 2015 | 39 | 0.470 |
Why?
| | Pandemics | 1 | 2020 | 595 | 0.470 |
Why?
| | Endoderm | 1 | 2015 | 2 | 0.470 |
Why?
| | Diabetes, Gestational | 1 | 2016 | 52 | 0.470 |
Why?
| | Diethylstilbestrol | 2 | 2008 | 12 | 0.460 |
Why?
| | Embryo Implantation | 1 | 2015 | 5 | 0.460 |
Why?
| | Transcriptional Activation | 3 | 2013 | 128 | 0.460 |
Why?
| | RNA, Untranslated | 1 | 2015 | 15 | 0.450 |
Why?
| | Mesoderm | 1 | 2015 | 30 | 0.450 |
Why?
| | Organoids | 1 | 2015 | 41 | 0.450 |
Why?
| | Histone Code | 1 | 2015 | 32 | 0.450 |
Why?
| | Cell Differentiation | 3 | 2015 | 681 | 0.450 |
Why?
| | Oxidative Stress | 4 | 2015 | 820 | 0.450 |
Why?
| | Estrogen Receptor alpha | 6 | 2019 | 85 | 0.440 |
Why?
| | Risk Factors | 9 | 2024 | 4018 | 0.440 |
Why?
| | Maternal-Fetal Exchange | 2 | 2020 | 48 | 0.440 |
Why?
| | Urinary Bladder Neck Obstruction | 1 | 2015 | 9 | 0.440 |
Why?
| | Forkhead Transcription Factors | 2 | 2012 | 120 | 0.440 |
Why?
| | SEER Program | 1 | 2015 | 106 | 0.430 |
Why?
| | Cyclopentanes | 1 | 2014 | 12 | 0.430 |
Why?
| | Quinolines | 1 | 2014 | 44 | 0.420 |
Why?
| | Endocrinology | 1 | 2014 | 11 | 0.420 |
Why?
| | Ovarian Neoplasms | 2 | 2010 | 459 | 0.410 |
Why?
| | Molecular Sequence Data | 8 | 2015 | 759 | 0.410 |
Why?
| | Cadmium | 2 | 2017 | 21 | 0.410 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 193 | 0.400 |
Why?
| | Adult | 18 | 2025 | 14541 | 0.390 |
Why?
| | Histone Acetyltransferases | 1 | 2013 | 26 | 0.390 |
Why?
| | Calcium-Binding Proteins | 2 | 2011 | 58 | 0.390 |
Why?
| | Toluene 2,4-Diisocyanate | 1 | 2013 | 1 | 0.390 |
Why?
| | Genomic Imprinting | 3 | 2008 | 11 | 0.390 |
Why?
| | Androgens | 4 | 2022 | 70 | 0.390 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 190 | 0.390 |
Why?
| | Cell Division | 1 | 2014 | 289 | 0.390 |
Why?
| | Integrin alpha6 | 1 | 2012 | 2 | 0.380 |
Why?
| | Base Sequence | 7 | 2015 | 620 | 0.380 |
Why?
| | Laminin | 1 | 2012 | 20 | 0.380 |
Why?
| | Umbilical Cord | 1 | 2013 | 36 | 0.370 |
Why?
| | RNA, Small Interfering | 6 | 2016 | 214 | 0.370 |
Why?
| | Mitogen-Activated Protein Kinase Phosphatases | 1 | 2012 | 3 | 0.370 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2012 | 4 | 0.370 |
Why?
| | Firefighters | 1 | 2012 | 3 | 0.370 |
Why?
| | Receptors, Androgen | 4 | 2022 | 48 | 0.370 |
Why?
| | Polycyclic Compounds | 1 | 2012 | 8 | 0.360 |
Why?
| | Occupational Diseases | 1 | 2013 | 82 | 0.360 |
Why?
| | Mass Screening | 1 | 2015 | 362 | 0.360 |
Why?
| | HMGN Proteins | 1 | 2011 | 1 | 0.350 |
Why?
| | Histones | 6 | 2016 | 318 | 0.350 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 523 | 0.350 |
Why?
| | Metals, Heavy | 3 | 2018 | 11 | 0.340 |
Why?
| | Mothers | 2 | 2016 | 269 | 0.340 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 302 | 0.340 |
Why?
| | Endocrine Glands | 1 | 2011 | 5 | 0.330 |
Why?
| | Risk | 4 | 2017 | 306 | 0.330 |
Why?
| | Endocrine System Diseases | 1 | 2011 | 9 | 0.330 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2010 | 21 | 0.330 |
Why?
| | Gene Silencing | 2 | 2010 | 122 | 0.330 |
Why?
| | Hazardous Substances | 1 | 2010 | 17 | 0.330 |
Why?
| | RNA | 2 | 2012 | 173 | 0.320 |
Why?
| | Prolactin | 1 | 2010 | 42 | 0.320 |
Why?
| | Nervous System | 1 | 2010 | 32 | 0.320 |
Why?
| | Liver Neoplasms | 3 | 2024 | 347 | 0.320 |
Why?
| | RNA, Messenger | 8 | 2022 | 1133 | 0.320 |
Why?
| | Membrane Proteins | 2 | 2010 | 333 | 0.320 |
Why?
| | Immunohistochemistry | 8 | 2016 | 975 | 0.320 |
Why?
| | Genetic Vectors | 1 | 2010 | 127 | 0.310 |
Why?
| | Introns | 1 | 2010 | 51 | 0.310 |
Why?
| | Placenta | 2 | 2025 | 146 | 0.310 |
Why?
| | Mice | 15 | 2024 | 5982 | 0.310 |
Why?
| | Proteins | 3 | 2008 | 351 | 0.300 |
Why?
| | Disease Models, Animal | 7 | 2024 | 1517 | 0.300 |
Why?
| | Anticarcinogenic Agents | 2 | 2006 | 32 | 0.290 |
Why?
| | Coenzyme A Ligases | 1 | 2009 | 6 | 0.290 |
Why?
| | Testis | 2 | 2021 | 74 | 0.280 |
Why?
| | Orphan Nuclear Receptors | 2 | 2019 | 14 | 0.280 |
Why?
| | Colon | 1 | 2009 | 106 | 0.280 |
Why?
| | Antigens, Neoplasm | 1 | 2009 | 146 | 0.280 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 452 | 0.270 |
Why?
| | Fetus | 1 | 2009 | 191 | 0.270 |
Why?
| | Cells, Cultured | 7 | 2019 | 1569 | 0.270 |
Why?
| | Deoxyguanosine | 2 | 2007 | 27 | 0.270 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 44 | 0.260 |
Why?
| | Age Factors | 4 | 2015 | 1136 | 0.260 |
Why?
| | Ethinyl Estradiol | 2 | 2018 | 8 | 0.260 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 162 | 0.260 |
Why?
| | Middle Aged | 15 | 2021 | 13422 | 0.250 |
Why?
| | Metabolome | 2 | 2025 | 109 | 0.250 |
Why?
| | Apigenin | 1 | 2006 | 7 | 0.250 |
Why?
| | Estrogen Receptor Modulators | 1 | 2006 | 5 | 0.250 |
Why?
| | Molecular Biology | 1 | 2007 | 27 | 0.250 |
Why?
| | Cell Line | 4 | 2016 | 1016 | 0.250 |
Why?
| | 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 6 | 0.240 |
Why?
| | Protein Isoforms | 4 | 2013 | 124 | 0.240 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2024 | 213 | 0.240 |
Why?
| | Lysine | 3 | 2015 | 91 | 0.240 |
Why?
| | Epithelium | 3 | 2014 | 64 | 0.240 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2014 | 181 | 0.240 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2014 | 56 | 0.230 |
Why?
| | Proteomics | 1 | 2008 | 337 | 0.230 |
Why?
| | DNA Primers | 3 | 2012 | 202 | 0.230 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2005 | 26 | 0.220 |
Why?
| | Carcinogens | 3 | 2015 | 194 | 0.220 |
Why?
| | Polychlorinated Biphenyls | 2 | 2018 | 36 | 0.220 |
Why?
| | Animals, Newborn | 5 | 2018 | 357 | 0.210 |
Why?
| | NF-kappa B | 1 | 2006 | 327 | 0.210 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 423 | 0.210 |
Why?
| | Estrogen Antagonists | 2 | 2012 | 21 | 0.210 |
Why?
| | Reproducibility of Results | 6 | 2020 | 1221 | 0.200 |
Why?
| | Thyroid Hormones | 2 | 2016 | 23 | 0.200 |
Why?
| | Infant, Newborn | 6 | 2025 | 2913 | 0.200 |
Why?
| | Antioxidants | 1 | 2006 | 264 | 0.200 |
Why?
| | Mice, Knockout | 2 | 2024 | 910 | 0.200 |
Why?
| | beta Catenin | 1 | 2024 | 107 | 0.200 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 98 | 0.200 |
Why?
| | Stem Cells | 2 | 2015 | 189 | 0.190 |
Why?
| | Interferons | 2 | 2015 | 39 | 0.190 |
Why?
| | Kidney | 1 | 2007 | 717 | 0.190 |
Why?
| | Acetylation | 3 | 2015 | 97 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 2 | 2020 | 130 | 0.190 |
Why?
| | Immediate-Early Proteins | 1 | 2002 | 18 | 0.180 |
Why?
| | Models, Biological | 5 | 2017 | 737 | 0.180 |
Why?
| | Arabidopsis Proteins | 1 | 2002 | 25 | 0.180 |
Why?
| | Pregnancy Outcome | 2 | 2017 | 231 | 0.180 |
Why?
| | Cohort Studies | 4 | 2016 | 1557 | 0.180 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2021 | 30 | 0.170 |
Why?
| | Inheritance Patterns | 1 | 2021 | 22 | 0.170 |
Why?
| | Gene Expression | 3 | 2011 | 618 | 0.170 |
Why?
| | Recycling | 2 | 2018 | 3 | 0.170 |
Why?
| | Integrin alphaVbeta3 | 1 | 2021 | 4 | 0.170 |
Why?
| | Incineration | 1 | 2021 | 5 | 0.170 |
Why?
| | Infertility, Female | 1 | 2021 | 18 | 0.170 |
Why?
| | Endometriosis | 1 | 2021 | 15 | 0.170 |
Why?
| | Endometrium | 1 | 2021 | 43 | 0.170 |
Why?
| | HEK293 Cells | 4 | 2016 | 235 | 0.170 |
Why?
| | Repressor Proteins | 2 | 2014 | 149 | 0.170 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 64 | 0.160 |
Why?
| | Linear Models | 2 | 2019 | 287 | 0.160 |
Why?
| | Mammary Glands, Animal | 2 | 2020 | 68 | 0.160 |
Why?
| | Hypesthesia | 1 | 2020 | 16 | 0.160 |
Why?
| | Loneliness | 1 | 2020 | 16 | 0.160 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2008 | 412 | 0.160 |
Why?
| | Child | 4 | 2018 | 7384 | 0.160 |
Why?
| | Memory Disorders | 1 | 2020 | 47 | 0.160 |
Why?
| | Life Style | 2 | 2019 | 150 | 0.160 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2016 | 48 | 0.160 |
Why?
| | Tissue Array Analysis | 4 | 2016 | 45 | 0.160 |
Why?
| | DNA Modification Methylases | 1 | 2020 | 29 | 0.160 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2020 | 21 | 0.160 |
Why?
| | DNA Repair Enzymes | 1 | 2020 | 44 | 0.160 |
Why?
| | Risk Assessment | 7 | 2016 | 1368 | 0.160 |
Why?
| | Pyruvate Kinase | 1 | 2020 | 7 | 0.160 |
Why?
| | Phenotype | 2 | 2015 | 803 | 0.150 |
Why?
| | Aged | 11 | 2020 | 10430 | 0.150 |
Why?
| | Birth Weight | 3 | 2017 | 119 | 0.150 |
Why?
| | Fear | 1 | 2020 | 85 | 0.150 |
Why?
| | Neoplasm Staging | 3 | 2014 | 774 | 0.150 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 97 | 0.150 |
Why?
| | Random Allocation | 2 | 2017 | 284 | 0.150 |
Why?
| | Neoplasm Metastasis | 2 | 2014 | 237 | 0.150 |
Why?
| | Mice, Transgenic | 2 | 2015 | 561 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2016 | 235 | 0.150 |
Why?
| | Methylation | 2 | 2020 | 127 | 0.150 |
Why?
| | Endometrial Neoplasms | 1 | 2020 | 143 | 0.150 |
Why?
| | Blotting, Western | 3 | 2016 | 587 | 0.150 |
Why?
| | Glioma | 1 | 2020 | 83 | 0.150 |
Why?
| | Adolescent | 4 | 2021 | 6912 | 0.150 |
Why?
| | Gonadal Steroid Hormones | 2 | 2011 | 39 | 0.150 |
Why?
| | Collagen Type III | 1 | 2019 | 7 | 0.150 |
Why?
| | Subcellular Fractions | 2 | 2012 | 33 | 0.150 |
Why?
| | Protein Binding | 3 | 2011 | 670 | 0.140 |
Why?
| | Urethra | 2 | 2020 | 98 | 0.140 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 233 | 0.140 |
Why?
| | Models, Genetic | 2 | 2011 | 169 | 0.140 |
Why?
| | Binding Sites | 3 | 2022 | 373 | 0.140 |
Why?
| | Liver Failure, Acute | 1 | 2019 | 57 | 0.140 |
Why?
| | Young Adult | 6 | 2025 | 4514 | 0.140 |
Why?
| | Collagen Type I | 1 | 2019 | 83 | 0.140 |
Why?
| | Methylmercury Compounds | 1 | 2018 | 4 | 0.140 |
Why?
| | Reactive Oxygen Species | 2 | 2015 | 421 | 0.140 |
Why?
| | Denmark | 1 | 2018 | 23 | 0.140 |
Why?
| | Prognosis | 4 | 2017 | 2118 | 0.140 |
Why?
| | Age Distribution | 2 | 2015 | 175 | 0.140 |
Why?
| | Computational Biology | 2 | 2017 | 209 | 0.140 |
Why?
| | Hair | 1 | 2018 | 29 | 0.140 |
Why?
| | Incidence | 3 | 2017 | 1085 | 0.140 |
Why?
| | T-Lymphocytes | 2 | 2017 | 320 | 0.130 |
Why?
| | Survival Analysis | 2 | 2016 | 659 | 0.130 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 54 | 0.130 |
Why?
| | Urethane | 1 | 2017 | 5 | 0.130 |
Why?
| | Histone Demethylases | 1 | 2017 | 22 | 0.130 |
Why?
| | Antigens, CD1 | 1 | 2017 | 9 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 25 | 0.130 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2008 | 11 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 228 | 0.130 |
Why?
| | Tumor Cells, Cultured | 2 | 2014 | 441 | 0.130 |
Why?
| | Fibroblasts | 1 | 2019 | 363 | 0.120 |
Why?
| | Cholesterol | 1 | 2017 | 161 | 0.120 |
Why?
| | Hippocampus | 1 | 2018 | 195 | 0.120 |
Why?
| | Gonads | 1 | 2016 | 6 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2014 | 228 | 0.120 |
Why?
| | 5-Methylcytosine | 1 | 2016 | 16 | 0.120 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 14 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2020 | 319 | 0.120 |
Why?
| | Genetic Loci | 1 | 2016 | 48 | 0.120 |
Why?
| | Soil Pollutants | 1 | 2016 | 13 | 0.120 |
Why?
| | Dust | 1 | 2016 | 24 | 0.120 |
Why?
| | Methyltransferases | 1 | 2016 | 28 | 0.120 |
Why?
| | Soil | 1 | 2016 | 27 | 0.120 |
Why?
| | Fetal Development | 1 | 2016 | 50 | 0.120 |
Why?
| | Exercise | 1 | 2020 | 561 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 221 | 0.120 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 56 | 0.120 |
Why?
| | Myocardium | 1 | 2019 | 471 | 0.120 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2015 | 4 | 0.120 |
Why?
| | Genital Neoplasms, Male | 1 | 2015 | 3 | 0.120 |
Why?
| | Logistic Models | 1 | 2018 | 947 | 0.120 |
Why?
| | Regression Analysis | 2 | 2015 | 391 | 0.120 |
Why?
| | Immunologic Surveillance | 1 | 2015 | 10 | 0.120 |
Why?
| | Advanced Oxidation Protein Products | 1 | 2015 | 1 | 0.110 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 99 | 0.110 |
Why?
| | Cell Survival | 2 | 2008 | 600 | 0.110 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2015 | 50 | 0.110 |
Why?
| | Exosomes | 1 | 2016 | 58 | 0.110 |
Why?
| | Environment | 1 | 2016 | 87 | 0.110 |
Why?
| | Spectrometry, Fluorescence | 1 | 2015 | 45 | 0.110 |
Why?
| | Prostatectomy | 1 | 2016 | 84 | 0.110 |
Why?
| | Isoenzymes | 2 | 2006 | 165 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2015 | 45 | 0.110 |
Why?
| | Genital Neoplasms, Female | 1 | 2015 | 48 | 0.110 |
Why?
| | Mammaglobin B | 1 | 2015 | 1 | 0.110 |
Why?
| | Weaning | 1 | 2015 | 32 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2015 | 238 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2020 | 645 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2015 | 101 | 0.110 |
Why?
| | Hyperplasia | 1 | 2015 | 98 | 0.110 |
Why?
| | Up-Regulation | 4 | 2019 | 456 | 0.110 |
Why?
| | Precancerous Conditions | 2 | 2006 | 87 | 0.110 |
Why?
| | Gestational Age | 1 | 2016 | 394 | 0.110 |
Why?
| | Inflammasomes | 1 | 2015 | 66 | 0.110 |
Why?
| | Schools | 1 | 2016 | 185 | 0.110 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2014 | 48 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 134 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 869 | 0.110 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 79 | 0.100 |
Why?
| | Erectile Dysfunction | 1 | 2015 | 94 | 0.100 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2014 | 20 | 0.100 |
Why?
| | Protein Processing, Post-Translational | 2 | 2012 | 149 | 0.100 |
Why?
| | Alleles | 1 | 2015 | 277 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 60 | 0.100 |
Why?
| | History, 20th Century | 1 | 2014 | 97 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 487 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 330 | 0.100 |
Why?
| | Gene Deletion | 1 | 2015 | 279 | 0.100 |
Why?
| | Age of Onset | 1 | 2014 | 109 | 0.100 |
Why?
| | Tamoxifen | 2 | 2012 | 60 | 0.100 |
Why?
| | Methacholine Chloride | 1 | 2013 | 3 | 0.100 |
Why?
| | Nitrates | 1 | 2013 | 30 | 0.100 |
Why?
| | Sp1 Transcription Factor | 2 | 2024 | 20 | 0.100 |
Why?
| | Ohio | 1 | 2013 | 45 | 0.100 |
Why?
| | Hydroxylation | 1 | 2013 | 64 | 0.100 |
Why?
| | China | 3 | 2018 | 135 | 0.100 |
Why?
| | Exons | 1 | 2013 | 100 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 2012 | 4 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 1925 | 0.090 |
Why?
| | Metabolomics | 2 | 2025 | 156 | 0.090 |
Why?
| | Flow Cytometry | 2 | 2014 | 400 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2013 | 158 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2016 | 2318 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 128 | 0.090 |
Why?
| | Oncogene Proteins | 1 | 2012 | 19 | 0.090 |
Why?
| | Saliva | 1 | 2012 | 56 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 64 | 0.090 |
Why?
| | Eyelids | 1 | 2012 | 27 | 0.090 |
Why?
| | Ovary | 2 | 2020 | 103 | 0.090 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 36 | 0.090 |
Why?
| | Smoke | 1 | 2012 | 18 | 0.090 |
Why?
| | Cell Adhesion | 1 | 2012 | 163 | 0.090 |
Why?
| | Mice, Nude | 4 | 2014 | 232 | 0.090 |
Why?
| | In Situ Hybridization | 2 | 2010 | 69 | 0.090 |
Why?
| | Child, Preschool | 2 | 2012 | 4164 | 0.090 |
Why?
| | Leukocyte Count | 1 | 2012 | 71 | 0.090 |
Why?
| | RNA Splicing | 1 | 2012 | 43 | 0.090 |
Why?
| | Antibodies | 2 | 2012 | 147 | 0.090 |
Why?
| | Phytoestrogens | 2 | 2014 | 23 | 0.090 |
Why?
| | Phosphorylation | 3 | 2020 | 533 | 0.090 |
Why?
| | Azacitidine | 1 | 2011 | 39 | 0.090 |
Why?
| | Carrier Proteins | 1 | 2013 | 315 | 0.090 |
Why?
| | Cell Cycle | 2 | 2012 | 237 | 0.080 |
Why?
| | Peptide Hormones | 1 | 2011 | 4 | 0.080 |
Why?
| | Adult Stem Cells | 1 | 2011 | 12 | 0.080 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 36 | 0.080 |
Why?
| | Nitric Oxide | 1 | 2012 | 233 | 0.080 |
Why?
| | Biomedical Research | 1 | 2014 | 267 | 0.080 |
Why?
| | Calcitriol | 1 | 2011 | 39 | 0.080 |
Why?
| | Tubulin Modulators | 1 | 2011 | 28 | 0.080 |
Why?
| | Calgranulin B | 1 | 2010 | 4 | 0.080 |
Why?
| | Environmental Pollution | 1 | 2010 | 14 | 0.080 |
Why?
| | Bromocriptine | 1 | 2010 | 5 | 0.080 |
Why?
| | Chemokine CXCL13 | 1 | 2010 | 6 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 75 | 0.080 |
Why?
| | Muscle Proteins | 1 | 2013 | 350 | 0.080 |
Why?
| | Tretinoin | 1 | 2011 | 53 | 0.080 |
Why?
| | Cell Nucleus | 2 | 2016 | 187 | 0.080 |
Why?
| | Paclitaxel | 1 | 2011 | 91 | 0.080 |
Why?
| | United States | 4 | 2015 | 5413 | 0.080 |
Why?
| | Feedback, Physiological | 1 | 2010 | 12 | 0.080 |
Why?
| | Genes, abl | 1 | 2010 | 2 | 0.080 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 71 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 140 | 0.080 |
Why?
| | Staining and Labeling | 2 | 2016 | 94 | 0.080 |
Why?
| | Autoimmunity | 1 | 2010 | 34 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2010 | 88 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 138 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2010 | 466 | 0.070 |
Why?
| | New York City | 1 | 2009 | 26 | 0.070 |
Why?
| | Adenoma, Villous | 1 | 2009 | 1 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 445 | 0.070 |
Why?
| | Ecotoxicology | 1 | 2008 | 4 | 0.070 |
Why?
| | Administration, Oral | 2 | 2010 | 456 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2009 | 69 | 0.070 |
Why?
| | Biopsy | 2 | 2021 | 600 | 0.070 |
Why?
| | Genital Diseases, Female | 1 | 2008 | 18 | 0.070 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.070 |
Why?
| | Public Health Practice | 1 | 2008 | 42 | 0.070 |
Why?
| | ROC Curve | 1 | 2009 | 246 | 0.070 |
Why?
| | Apoptosis | 1 | 2013 | 1139 | 0.070 |
Why?
| | Behavior, Animal | 2 | 2020 | 187 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 181 | 0.070 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2007 | 12 | 0.070 |
Why?
| | Microdissection | 1 | 2007 | 20 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 49 | 0.060 |
Why?
| | Lasers | 1 | 2007 | 64 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 64 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 350 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2015 | 1212 | 0.060 |
Why?
| | Presenilin-2 | 1 | 2006 | 2 | 0.060 |
Why?
| | Yeasts | 1 | 2006 | 8 | 0.060 |
Why?
| | Proteome | 1 | 2008 | 178 | 0.060 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 19 | 0.060 |
Why?
| | Dimerization | 1 | 2006 | 50 | 0.060 |
Why?
| | Caspase 3 | 1 | 2006 | 92 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 392 | 0.060 |
Why?
| | Growth Differentiation Factor 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2016 | 6821 | 0.060 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 268 | 0.060 |
Why?
| | Consensus | 1 | 2007 | 206 | 0.060 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 333 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 267 | 0.060 |
Why?
| | Interleukin-12 | 1 | 2006 | 26 | 0.060 |
Why?
| | Spinacia oleracea | 1 | 2006 | 8 | 0.060 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2006 | 52 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2006 | 85 | 0.060 |
Why?
| | Phytotherapy | 1 | 2006 | 45 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 107 | 0.060 |
Why?
| | Organ Size | 2 | 2016 | 228 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1232 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 563 | 0.060 |
Why?
| | Models, Molecular | 1 | 2006 | 352 | 0.060 |
Why?
| | Phthalic Acids | 1 | 2025 | 7 | 0.060 |
Why?
| | MCF-7 Cells | 2 | 2016 | 65 | 0.050 |
Why?
| | Alternative Splicing | 1 | 2005 | 61 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2025 | 122 | 0.050 |
Why?
| | Down-Regulation | 2 | 2021 | 344 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2006 | 202 | 0.050 |
Why?
| | TATA Box | 1 | 2004 | 8 | 0.050 |
Why?
| | Dinucleoside Phosphates | 1 | 2004 | 7 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2017 | 333 | 0.050 |
Why?
| | Transfection | 1 | 2005 | 359 | 0.050 |
Why?
| | Infant | 1 | 2012 | 3808 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 2 | 2017 | 255 | 0.050 |
Why?
| | Orchiectomy | 1 | 2003 | 38 | 0.050 |
Why?
| | Oxidoreductases | 1 | 2003 | 57 | 0.050 |
Why?
| | Androgen-Binding Protein | 1 | 2003 | 1 | 0.050 |
Why?
| | Prostatic Secretory Proteins | 1 | 2003 | 1 | 0.050 |
Why?
| | Seminal Vesicle Secretory Proteins | 1 | 2003 | 1 | 0.050 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 70 | 0.050 |
Why?
| | Aldehydes | 1 | 2003 | 81 | 0.050 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Clusterin | 1 | 2003 | 8 | 0.050 |
Why?
| | Plant Extracts | 1 | 2006 | 200 | 0.050 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2003 | 5 | 0.050 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2003 | 7 | 0.050 |
Why?
| | Glutathione Reductase | 1 | 2003 | 14 | 0.050 |
Why?
| | Postoperative Period | 1 | 2003 | 169 | 0.050 |
Why?
| | Glutathione Peroxidase | 1 | 2003 | 23 | 0.050 |
Why?
| | Cytoskeleton | 1 | 2003 | 39 | 0.050 |
Why?
| | Malondialdehyde | 1 | 2003 | 55 | 0.050 |
Why?
| | Catalase | 1 | 2003 | 72 | 0.050 |
Why?
| | Regeneration | 1 | 2003 | 83 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 98 | 0.050 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 92 | 0.050 |
Why?
| | Molecular Chaperones | 1 | 2003 | 76 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2003 | 122 | 0.050 |
Why?
| | Glycoproteins | 1 | 2003 | 121 | 0.050 |
Why?
| | Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Vasoactive Intestinal Peptide | 1 | 2002 | 3 | 0.050 |
Why?
| | Radioimmunoassay | 1 | 2002 | 41 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 281 | 0.050 |
Why?
| | Early Growth Response Protein 1 | 1 | 2002 | 34 | 0.050 |
Why?
| | Peer Review | 1 | 2002 | 10 | 0.050 |
Why?
| | Endocrine System | 1 | 2002 | 16 | 0.040 |
Why?
| | Sp3 Transcription Factor | 1 | 2022 | 5 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2022 | 15 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2002 | 89 | 0.040 |
Why?
| | Adenosine Triphosphatases | 1 | 2002 | 92 | 0.040 |
Why?
| | Mutation | 1 | 2007 | 1338 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 238 | 0.040 |
Why?
| | Plant Proteins | 1 | 2002 | 72 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2021 | 53 | 0.040 |
Why?
| | Amino Acids | 1 | 2023 | 382 | 0.040 |
Why?
| | Trans-Activators | 1 | 2002 | 139 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2015 | 3495 | 0.040 |
Why?
| | Mitochondria | 1 | 2005 | 447 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 42 | 0.040 |
Why?
| | Alcohol Oxidoreductases | 1 | 2020 | 13 | 0.040 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2020 | 4 | 0.040 |
Why?
| | Thyroid Gland | 1 | 2020 | 76 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 147 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2019 | 38 | 0.040 |
Why?
| | Transcription Factors | 1 | 2002 | 571 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2019 | 104 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2019 | 192 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 1723 | 0.030 |
Why?
| | Prospective Studies | 2 | 2015 | 2412 | 0.030 |
Why?
| | Fibrosis | 1 | 2019 | 198 | 0.030 |
Why?
| | Apgar Score | 1 | 2017 | 26 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 727 | 0.030 |
Why?
| | Heart | 1 | 2020 | 350 | 0.030 |
Why?
| | United States Environmental Protection Agency | 2 | 2007 | 8 | 0.030 |
Why?
| | Diet, Atherogenic | 1 | 2017 | 10 | 0.030 |
Why?
| | Gasoline | 1 | 2017 | 2 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 39 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 55 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2007 | 43 | 0.030 |
Why?
| | Endosomes | 1 | 2017 | 35 | 0.030 |
Why?
| | Endocytosis | 1 | 2017 | 47 | 0.030 |
Why?
| | Time Factors | 2 | 2014 | 2992 | 0.030 |
Why?
| | Thyroid Function Tests | 1 | 2016 | 28 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 747 | 0.030 |
Why?
| | Lung | 1 | 2020 | 481 | 0.030 |
Why?
| | Acetaminophen | 1 | 2019 | 277 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 181 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2017 | 189 | 0.030 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 21 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 216 | 0.030 |
Why?
| | Drug Implants | 1 | 2015 | 35 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 128 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 180 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 148 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 163 | 0.030 |
Why?
| | Sp Transcription Factors | 1 | 2014 | 6 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 8 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2015 | 67 | 0.030 |
Why?
| | Triterpenes | 1 | 2014 | 11 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 86 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 78 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2015 | 112 | 0.030 |
Why?
| | HMGA Proteins | 1 | 2014 | 2 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2014 | 71 | 0.030 |
Why?
| | Caspase 7 | 1 | 2013 | 7 | 0.030 |
Why?
| | Genome | 1 | 2014 | 58 | 0.030 |
Why?
| | 5' Untranslated Regions | 1 | 2013 | 29 | 0.020 |
Why?
| | Weight Gain | 1 | 2015 | 245 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2013 | 52 | 0.020 |
Why?
| | Transcription Factor AP-2 | 1 | 2012 | 3 | 0.020 |
Why?
| | Laser Capture Microdissection | 1 | 2012 | 6 | 0.020 |
Why?
| | Receptors, Steroid | 1 | 2012 | 20 | 0.020 |
Why?
| | Progesterone | 1 | 2012 | 57 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2012 | 128 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2012 | 174 | 0.020 |
Why?
| | Serum Response Factor | 1 | 2012 | 45 | 0.020 |
Why?
| | Blood Glucose | 1 | 2015 | 491 | 0.020 |
Why?
| | Cell Death | 1 | 2012 | 171 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 248 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 647 | 0.020 |
Why?
| | Cisplatin | 1 | 2013 | 282 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 84 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 92 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 127 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 563 | 0.020 |
Why?
| | Albumins | 1 | 2011 | 29 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 75 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 69 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2010 | 55 | 0.020 |
Why?
| | STAT1 Transcription Factor | 1 | 2010 | 28 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 310 | 0.020 |
Why?
| | Carcinoma, Lobular | 1 | 2010 | 32 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2010 | 68 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 47 | 0.020 |
Why?
| | Nanoparticles | 1 | 2011 | 133 | 0.020 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2010 | 89 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 148 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 14 | 0.020 |
Why?
| | Animals, Wild | 1 | 2007 | 10 | 0.020 |
Why?
| | North Carolina | 1 | 2007 | 53 | 0.020 |
Why?
| | Models, Animal | 1 | 2007 | 233 | 0.020 |
Why?
| | Public Health | 1 | 2002 | 231 | 0.010 |
Why?
|
|
Ho's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|